Risperidone for treatment-refractory major depressive disorder: a randomized trial.

Area of Science:

• Psychiatry
• Clinical Pharmacology
• Neuroscience

Background:

• Major depressive disorder (MDD) presents significant global health challenges.
• Antidepressant monotherapy often yields suboptimal results, necessitating augmentation strategies.

Purpose of the Study:

• To evaluate the efficacy of risperidone as an augmentation therapy for adults with MDD.
• To assess the impact of risperidone on depression symptom severity, response rates, and remission.

Main Methods:

• A multicenter, double-blind, placebo-controlled, randomized trial involving 274 outpatients with MDD.
• Patients received standard antidepressants and were augmented with either risperidone (1-2 mg/d) or placebo for 6 weeks.
• Depression symptoms were assessed using the Hamilton Rating Scale for Depression (HRSD-17).

Main Results:

• Risperidone augmentation led to a statistically significant reduction in mean HRSD-17 scores compared to placebo.
• Higher rates of depression remission (24.5% vs. 10.7%) and response (46.2% vs. 29.5%) were observed in the risperidone group.
• Common adverse events included headache, somnolence, and dry mouth.

Conclusions:

• Risperidone augmentation is effective in reducing depressive symptoms and improving remission and response rates in patients with MDD.
• The study provides evidence for risperidone's utility as an augmentation strategy for treatment-resistant depression.
• Limitations include diverse antidepressant use and a short augmentation therapy duration.